Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Traws Pharma ( (TRAW) ) has shared an announcement.
On May 15, 2026, Traws Pharma reported first-quarter 2026 results and outlined progress across its antiviral pipeline, highlighted by an April 15, 2026 private investment in public equity of up to $60 million, including $10 million received at closing and additional milestone-based warrants expected to fund operations into the first quarter of 2027 and complete a human influenza challenge trial for tivoxavir marboxil. The company is advancing tivoxavir marboxil toward a Q2 2026 human challenge study in the U.K. while working to resolve an FDA clinical hold on its U.S. IND, and it is rapidly moving a hantavirus clinical candidate forward in the wake of a recent high-profile outbreak, even as higher R&D spending and warrant-related fair value changes drove a net loss of $7.1 million for the quarter ended March 31, 2026, versus net income a year earlier.
As of March 31, 2026, Traws held $3.1 million in cash and cash equivalents, excluding the subsequent PIPE proceeds, and expects its enhanced capital base, together with existing resources, to support planned studies, including the influenza challenge trial, into early 2027. The quarter underscored a strategic pivot toward executing key clinical milestones in influenza prophylaxis and hantavirus treatment, potentially strengthening the company’s position in high-value antiviral and pandemic preparedness markets despite current operating losses and regulatory hurdles.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.
The score is held down primarily by weak financial performance (ongoing cash burn, negative equity, and non-recurring drivers of reported profitability). Technical momentum is a clear positive, while valuation appears low but is discounted due to earnings quality concerns. Earnings-call updates add moderate support via financing and trial progress, but regulatory and liquidity risks remain significant.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule antiviral therapies targeting critical respiratory viral threats, including seasonal influenza, H5N1 bird flu, hantavirus and COVID-19/Long COVID. Its lead candidate, tivoxavir marboxil, is being developed as a once-monthly oral prophylactic for influenza, with additional potential as a single-dose treatment for seasonal and pandemic flu, positioning the company in multi-billion-dollar antiviral and pandemic preparedness markets.
The company integrates antiviral drug development, medical intelligence and regulatory strategy to address difficult-to-treat or resistant viral strains, aiming to serve both commercial markets and government-driven stockpiling and preparedness initiatives. By advancing agents with activity against negative-strand RNA viruses and high-fatality infections such as hantavirus, Traws is seeking to expand its footprint in emerging infectious disease therapeutics and global health security.
Average Trading Volume: 2,087,190
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.7M
Find detailed analytics on TRAW stock on TipRanks’ Stock Analysis page.